Status:
TERMINATED
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
Lead Sponsor:
Celgene
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with ren...
Eligibility Criteria
Inclusion
- Metastatic Renal Cell Carcinoma.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
Exclusion
- Prior chemotherapy.
- Prior treatment with lenalidomide, thalidomide, pomalidomide, or sunitinib.
- Laboratory values outside normal ranges.
- Myocardial infarction (MI) within past 12 months.
- Current congestive heart failure.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00975806
Start Date
September 1 2009
End Date
October 1 2011
Last Update
November 25 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
2
Cleveland Clinic Main Campus
Cleveland, Ohio, United States, 44195
3
Tennessee Oncology
Nashville, Tennessee, United States, 37203